Evidence map›Paper›PMID 31556293›Full record

ArticleACS sensors2019

Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery.

Philippe Dauphin-Ducharme, Kyungae Yang, Netzahualcóyotl Arroyo-Currás, Kyle L Ploense, Yameng Zhang, Julian Gerson, Martin Kurnik, Tod E Kippin, Milan N Stojanovic, Kevin W Plaxco

Abstract read
In one paragraph

Article in ACS sensors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Philippe Dauphin-DucharmeORCID 0000-0002-0490-7115
Kyungae Yang
Netzahualcóyotl Arroyo-CurrásDepartment of Pharmacology and Molecular Sciences , Johns Hopkins School of Medicine , Baltimore , Maryland 21205 , United States.ORCID 0000-0002-2740-6276
Kyle L Ploense
Yameng Zhang
Julian Gerson
Tod E Kippin
Milan N Stojanovic

Funding

Bio-electrochemical detectors for in vivo continuous monitoringR01EB022015 · NIBIB · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI KIPPIN, TOD EDWARD, PLAXCO, KEVIN W · 2017 to 2025
$4.6M
Feedback controlled, ultra-high-precision drug deliveryR01AI145206 · NIAID · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI PLAXCO, KEVIN W · 2019 to 2023
$2.0M
NIAID NIH HHS R01 AI145206NIBIB NIH HHS R01 EB022015
6 · The paper itself

Abstract

The electrochemical aptamer-based (E-AB) sensing platform appears to be a convenient (rapid, single-step, and calibration-free) and modular approach to measure concentrations of specific molecules (irrespective of their chemical reactivity) directly in blood and even in situ in the living body. Given these attributes, the platform may thus provide significant opportunities to render therapeutic drug monitoring (the clinical practice in which dosing is adjusted in response to plasma drug measurements) as frequent and convenient as the measurement of blood sugar has become for diabetics. The ability to measure arbitrary molecules in the body in real time could even enable closed-loop feedback control over plasma drug levels in a manner analogous to the recently commercialized controlled blood sugar systems. As initial exploration of this, we describe here the selection of an aptamer against vancomycin, a narrow therapeutic window antibiotic for which therapeutic monitoring is a critical part of the standard of care, and its adaptation into an electrochemical aptamer-based (E-AB) sensor. Using this sensor, we then demonstrate: (i) rapid (seconds) and convenient (single-step and calibration-free) measurement of plasma vancomycin in finger-prick-scale samples of whole blood, (ii) high-precision measurement of subject-specific vancomycin pharmacokinetics (in a rat animal model), and (iii) high-precision, closed-loop feedback control over plasma levels of the drug (in a rat animal model). The ability to not only track (with continuous-glucose-monitor-like measurement frequency and convenience) but also actively control plasma drug levels provides an unprecedented route toward improving therapeutic drug monitoring and, more generally, the personalized, high-precision delivery of pharmacological interventions.

Indexed as

AnimalsAnti-Bacterial AgentsAptamers, NucleotideCattleDrug MonitoringElectrochemical TechniquesMaleRats, Sprague-DawleyVancomycinAnti-Bacterial AgentsAptamers, NucleotideVancomycincontrolled drug deliveryDNA aptamerelectrochemical DNA biosensorsquare-wave voltammetrytherapeutic drug monitoringvancomycin

Identifiers

PMID31556293
PMCPMC6886665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.